Llusern Scientific was pleased that two abstracts assessing the Lodestar UTI testing panel in clinical settings were published in the American Urology Association’s  Journal of Urology this month (May 2026).

The researchers found that Lodestar DX “demonstrated strong performance as a rapid and reliable alternative to standard MC&S and dipstick” and resulted in “meaningful improvements in management.”

The team from The Royal Berkshire NHS Foundation Trust, which included Professor Bob Yang, Saif Kazi and Clemence Musabyimana, presented posters based on the abstracts at the annual AUA congress in Washington (15-18 May) to an audience of international urologists.

The abstracts are available to read here:

Assessing the Lodestar DX uropathogen identifier as a rapid diagnostic alternative to conventional urine culture and dipstick for pre-operative screening

Optimising outpatient urology care with the Lodestar DX rapid urine analyser: Real-time uropathogen identification and antibiotic stewardship.

The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).